$LRCX

BRANDT ERIC sold $19.1M of LRCX

BRANDT ERIC sold 54,500 shares of LAM RESEARCH CORP (LRCX) at an average of $350.80 ($337.56–$364.00, $19.12M total) across 26 trades on 2026-06-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BRANDT ERIC
Published Jun 15, 2026, 4:27 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 15, 2026, 5:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LRCX
Neutral
medium confidence
Mentioned
$LRCX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LRCXNeutralLow
01

Why it matters

A director sold ~$19.1M of LRCX shares across 26 trades at $337.56–$364.00, executed 2026-06-11, under a pre-arranged 10b5-1 plan; this can slightly pressure sentiment but is not a fundamental catalyst.

02

Market read

Primary-source insider selling disclosure; likely modest sentiment impact only.

03

What to watch

Traders may overreact to insider sales; without accompanying buys, guidance changes, or operational news, the signal is usually secondary.

Relevance 6/10Novelty 8/10Timing: Filed 2026-06-15; transactions executed 2026-06-11.

Background

The article is an SEC Form 4 insider transaction disclosure for LAM Research (LRCX).

Company-level read

Ticker impact

$LRCXNeutralMedium confidence
Context

LRCX discloses a director’s open-market sale of 54,500 shares (~$19.1M) under a pre-arranged 10b5-1 plan on 2026-06-11.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless paired with other catalysts.

Evidence & confidence

The filing is primary-source (Form 4) and sizable in dollars, but it is explicitly under a pre-arranged 10b5-1 plan, which typically dampens market reaction.

Market effects

No direct sector read-through; this is company-specific insider activity in semicap equipment.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than a bearish view on LRCX fundamentals.

Key entities

  • LAM Research Corp

    Subject of the Form 4 insider transaction disclosure.

  • BRANDT ERIC

    Director who sold 54,500 shares of LRCX under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LRCXMed

The Memory Crunch Is Bigger Than Expected. 1 Top Stock to Buy on the Dip (Hint: Not Micron or Sandisk)

Lam Research (LRCX) is benefiting from a memory chip supply crunch, with revenue up 26% and earnings up 39% in fiscal 2026. The company expects 52% revenue growth and 71% earnings growth in the current quarter. Deloitte projects memory manufacturer capex to rise significantly, favoring Lam's semiconductor equipment sales. Analysts forecast 62% EPS growth for fiscal 2027, with potential for further upside.

$LRCXMedAI 8/10

Ministry approves Lam Research's NT$9.8 billion Taiwan investment

Taiwan's Ministry of Economic Affairs approved Lam Research's NT$9.835 billion (US$310 million) investment in its Taiwan subsidiary for semiconductor equipment R&D. Other approved investments include Zhen Ding Technology's NT$3 billion in Boardtek Electronics, Nuvoton's 15 billion yen in its Japan unit, and Foxconn's US$57.01 million in Mitsubishi Fuso Bus.